Retatrutide vs Tirzepatide: Head-to-Head Efficacy, Safety, and Dosing Comparison (2026)

A comparison of retatrutide vs tirzepatide as reported in published trials — weight loss data, side effect profiles, the doses reported in each trial protocol, and the regulatory status of each in 2026.

The Core Difference: Dual vs Triple Agonism

Tirzepatide (Mounjaro/Zepbound) is a dual agonist — it activates GLP-1 and GIP receptors. Retatrutide goes further, adding glucagon receptor activation, making it the first triple agonist in advanced trials — the triple vs dual agonist distinction at the centre of this GLP-1 comparison 2026. In the published mechanism literature, glucagon agonism increases energy expenditure and promotes hepatic fat oxidation, which is why the reported efficacy ceiling for retatrutide exceeds tirzepatide's.

In head-to-head context: tirzepatide's SURMOUNT-1 trial reported 22.5% mean weight loss at the highest dose — the tirzepatide weight loss percent most often cited in comparative reviews — while retatrutide's TRIUMPH-4 reported 28.7% mean weight loss (71.2 lbs) at the 12 mg trial step over 68 weeks, the highest efficacy recorded for any obesity pharmacotherapy to date. Cross-trial comparisons carry caveats (different populations, durations), but the direction is consistent across every dose pair in the reported data — the central retatrutide efficacy finding.

Weight Loss Trajectory and the Doses Reported in Trials

This is a dosing comparison of the trial protocols, not a schedule for anyone to follow. Tirzepatide's protocol titrated 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg weekly, with 5-week steps. Retatrutide's published trial ladder ran 0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg → 12 mg weekly — starting lower and reaching higher relative potency in the reported data.

Differences reported in the trials:

• Speed to effect: retatrutide's early titration phase produced rapid early losses (TRIUMPH-4 subjects averaged ~5% by week 12 in the reported data), with side effects clustering in escalation weeks.
• Side effects: both share nausea, vomiting, diarrhea, constipation in the reported safety data. Retatrutide adds glucagon-mediated effects — resting heart rate increases of a few BPM and more pronounced early fatigue — which the trial data describe as tapering as the body adapts.
• Muscle loss: neither drug spares lean mass by itself in the reported body-composition data. Both are studied alongside the same protein and resistance-training variables. Retatrutide's larger total loss means more attention to training through the deficit in the published analysis.
• Availability: tirzepatide is FDA-approved and widely prescribed; retatrutide is not FDA-approved, the FDA has stated it cannot be lawfully compounded under 503A/503B, and access in 2026 is via trial enrollment only. That regulatory gap is the central comparison point in the 2026 literature.

Cost, Availability, and the 2026 Regulatory Position

Tirzepatide's patent-protected list price runs ~$1,000/month at U.S. pharmacies, though copay programs and telehealth compounded variants exist (subject to shifting FDA enforcement). Retatrutide has no legal commercial price — trial participation, where available, is the only sanctioned access reported.

In the published guidance, the approved, physician-supervised option today carries an enormous real-world safety database, while retatrutide remains trial-only for significant obesity after approved options are exhausted. Research-grade retatrutide circulates on the gray market, but purity and accuracy are unverified in the literature — see our [retatrutide dosage calculator] for what verified concentration and volume conversion looks like.

Retatrutide efficacy figures reported here come from trial data. Retatrutide is investigational. It is not approved for human use by any regulator, no approved dosing exists, and the amounts above are reported from published trial protocols as research data — not as a schedule for anyone to follow.

📊 Dosage Calculator & Protocol Chart

Convert reported trial amounts into solution volumes for lab reference:

👉 Retatrutide Calculator — Concentration and volume conversions for reported research quantities, and for the reported dose steps in the published protocols.

👉 Full Retatrutide Research Overview — The published trial data, reported dose steps, and body-composition sub-study findings in one place.

Important Disclaimer

This article is for educational and research purposes only. Retatrutide is investigational and has not been approved by the FDA or any other regulator for human use. Tirzepatide is approved for specific indications as described in its label. The information provided here is synthesized from published research, clinical trial data, and community discussions. Nothing on this page is medical advice, and no peptide discussed here is offered for human use.

Keywords: retatrutide vs tirzepatide, triple vs dual agonist, GLP-1 comparison 2026, tirzepatide weight loss percent, retatrutide efficacy

Sources: Published research papers, clinical trial databases, community discussions, peptiq.io educational content